Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.09)
# 1,215
Out of 4,876 analysts
92
Total ratings
46.99%
Success rate
0.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $64 | $37.13 | +72.37% | 3 | Jun 20, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | $50 | $10.05 | +397.51% | 5 | Jun 18, 2025 | |
| QURE uniQure | Reiterates: Buy | $28 | $14.23 | +96.77% | 6 | May 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $55 → $45 | $9.61 | +368.26% | 2 | May 12, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $81 → $97 | $84.02 | +15.45% | 3 | May 8, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $195 → $189 | $142.69 | +32.45% | 4 | May 7, 2025 | |
| BEAM Beam Therapeutics | Maintains: Buy | $78 → $55 | $17.14 | +220.89% | 3 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $112 → $98 | $17.23 | +468.78% | 5 | May 7, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $65 → $64 | $39.78 | +60.88% | 5 | May 1, 2025 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $19 | $12.74 | +49.14% | 2 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $13.04 | +114.72% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $4.31 | - | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.65 | +579.25% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $12.35 | +37.65% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $5.69 | +163.62% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $558 | $443.40 | +25.85% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $46.70 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.14 | +358.94% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $2.97 | +640.74% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $18.45 | +62.60% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $54.10 | +103.33% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.20 | +2,316.67% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.33 | +3,233.33% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $318.25 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.41 | +1,061.83% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.03 | +184.50% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $28.07 | +338.19% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $12.37 | +336.54% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.07 | +5,507.48% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.65 | - | 3 | Jun 26, 2017 |
Ultragenyx Pharmaceutical
Jun 20, 2025
Reiterates: Buy
Price Target: $64
Current: $37.13
Upside: +72.37%
Dyne Therapeutics
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $10.05
Upside: +397.51%
uniQure
May 12, 2025
Reiterates: Buy
Price Target: $28
Current: $14.23
Upside: +96.77%
Intellia Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $9.61
Upside: +368.26%
Soleno Therapeutics
May 8, 2025
Maintains: Buy
Price Target: $81 → $97
Current: $84.02
Upside: +15.45%
Krystal Biotech
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $142.69
Upside: +32.45%
Beam Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $17.14
Upside: +220.89%
Sarepta Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $112 → $98
Current: $17.23
Upside: +468.78%
Ionis Pharmaceuticals
May 1, 2025
Maintains: Buy
Price Target: $65 → $64
Current: $39.78
Upside: +60.88%
Maze Therapeutics
Apr 2, 2025
Reiterates: Buy
Price Target: $19
Current: $12.74
Upside: +49.14%
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $13.04
Upside: +114.72%
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $4.31
Upside: -
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $2.65
Upside: +579.25%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $12.35
Upside: +37.65%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.69
Upside: +163.62%
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $443.40
Upside: +25.85%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $46.70
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.14
Upside: +358.94%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $2.97
Upside: +640.74%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $18.45
Upside: +62.60%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $54.10
Upside: +103.33%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.20
Upside: +2,316.67%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.33
Upside: +3,233.33%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $318.25
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $2.41
Upside: +1,061.83%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $7.03
Upside: +184.50%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $28.07
Upside: +338.19%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $12.37
Upside: +336.54%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.07
Upside: +5,507.48%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $33.65
Upside: -